Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy

FASEB J. 2003 Nov;17(14):1986-95. doi: 10.1096/fj.03-0053rev.

Abstract

Cyclooxygenase (COX) and lipoxygenase (LO) metabolic pathways are emerging as key regulators of cell proliferation and neo-angiogenesis. COX and LO inhibitors are being investigated as potential anticancer drugs and results from clinical trials seem to be encouraging. In this article we will review evidence of COX-2 and 5-LO involvement in cancer pathobiology, propose a model of integrated control of cell proliferation by these enzymes, and discuss the pharmacologic implications of this model.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Arachidonate 5-Lipoxygenase / physiology*
  • Cell Division
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Isoenzymes / physiology*
  • Lipoxygenase Inhibitors / therapeutic use
  • Membrane Proteins
  • Models, Biological
  • Neoplasms / blood supply
  • Neoplasms / drug therapy
  • Neoplasms / enzymology*
  • Neoplasms / etiology
  • Neovascularization, Pathologic
  • Prostaglandin-Endoperoxide Synthases / physiology*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Lipoxygenase Inhibitors
  • Membrane Proteins
  • Arachidonate 5-Lipoxygenase
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases